Works by Burris, Howard A.

Results: 151

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

Published in:

2017

By:

LoRusso, Patricia M.;
Infante, Jeffrey R.;
Kim, Kevin B.;
Burris, Howard A.;
Curt, Gregory;
Ugochi Emeribe;
Clemett, Delyth;
Tomkinson, Helen K.;
Cohen, Roger B.;
Burris, Howard A 3rd;
Emeribe, Ugochi

Publication type:

journal article

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Published in:

2017

By:

Burris, Howard;
Kurkjian, C.;
Hart, L.;
Pant, S.;
Murphy, P.;
Jones, S.;
Neuwirth, R.;
Patel, C.;
Zohren, F.;
Infante, J.;
Burris, Howard A 3rd;
Kurkjian, C D;
Murphy, P B;
Jones, S F;
Patel, C G;
Infante, J R

Publication type:

journal article

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Published in:

2016

By:

Burris, Howard;
Infante, Jeffrey;
Anthony Greco, F.;
Thompson, Dana;
Barton, John;
Bendell, Johanna;
Nambu, Yoshihiro;
Watanabe, Noriko;
Jones, Suzanne;
Burris, Howard A;
Infante, Jeffrey R;
Thompson, Dana S;
Barton, John H;
Bendell, Johanna C;
Jones, Suzanne F

Publication type:

journal article

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Published in:

2019

By:

Perez, Edith A.;
de Haas, Sanne Lysbet;
Eiermann, Wolfgang;
Barrios, Carlos H.;
Toi, Masakazu;
Im, Young-Hyuck;
Conte, Pier Franco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris III, Howard A.;
Stanzel, Sven;
Patre, Monika;
Ellis, Paul Anthony;
Burris, Howard A 3rd

Publication type:

journal article

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Published in:

2003

By:

Hainsworth, John D.;
Burris III, Howard A.;
Erland, Joan B.;
Baker, Margaret;
Scullin Jr., Daniel C.;
Shaffer, Don W.;
Greco, F. Anthony;
Burris, Howard A 3rd;
Scullin, Daniel C Jr;
Minnie Pearl Cancer Research Network

Publication type:

journal article

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Published in:

2019

By:

Perez, Edith A.;
de Haas, Sanne Lysbet;
Eiermann, Wolfgang;
Barrios, Carlos H.;
Toi, Masakazu;
Im, Young-Hyuck;
Conte, Pier Franco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris III, Howard A.;
Stanzel, Sven;
Patre, Monika;
Ellis, Paul Anthony;
Burris, Howard A 3rd

Publication type:

journal article

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Published in:

2019

By:

Perez, Edith A.;
Barrios, Carlos;
Eiermann, Wolfgang;
Toi, Masakazu;
Im, Young‐Hyuck;
Conte, Pierfranco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris, Howard A.;
Petersen, Jennifer A.;
De Haas, Sanne;
Hoersch, Silke;
Patre, Monika;
Ellis, Paul Anthony;
Im, Young-Hyuck;
Burris, Howard A 3rd

Publication type:

journal article

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.

Published in:

2018

By:

Spigel, David R.;
Burris, Howard A.;
Greco, F. Anthony;
Shih, Kent C.;
Gian, Victor G.;
Lipman, Andrew J.;
Daniel, Davey B.;
Waterhouse, David M.;
Finney, Lindsey;
Heymach, John V.;
Hainsworth, John D.;
Burris, Howard A 3rd

Publication type:

journal article

Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.

Published in:

2018

By:

Spigel, David R.;
Hainsworth, John D.;
Joseph, Mathew J.;
Shipley, Dianna L.;
Hagan, M. Kelly;
Thompson, Dana S.;
Burris, III, Howard A.;
Greco, F. Anthony;
Burris, Howard A 3rd

Publication type:

journal article

Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Published in:

2018

By:

Burris, Howard A.;
Burris, Howard A 3rd

Publication type:

journal article

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).

Published in:

Journal of Neuro-Oncology, 2019, v. 144, n. 2, p. 303, doi. 10.1007/s11060-019-03227-7

By:

Hainsworth, John D.;
Becker, Kevin P.;
Mekhail, Tarek;
Chowdhary, Sajeel A.;
Eakle, Janice Faulkner;
Wright, David;
Langdon, Robert M.;
Yost, Kathleen J.;
Padula, Gilbert Darin Anthony;
West-Osterfield, Kimberly;
Scarberry, Meredith;
Shaifer, Candice A.;
Shastry, Mythili;
Burris III, Howard A.;
Shih, Kent

Publication type:

Article

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.

Published in:

Journal of Neuro-Oncology, 2016, v. 129, n. 2, p. 281, doi. 10.1007/s11060-016-2172-3

By:

Shih, Kent;
Chowdhary, Sajeel;
Rosenblatt, Paul;
Weir, Alva;
Shepard, Gregg;
Williams, Jeffrey;
Shastry, Mythili;
Burris, Howard;
Hainsworth, John

Publication type:

Article

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.

Published in:

Oncologist, 2023, v. 28, n. 7, p. 640, doi. 10.1093/oncolo/oyad029

By:

Johnson, Melissa L;
Patel, Manish R;
Aljumaily, Raid;
Jones, Suzanne F;
Burris, Howard A;
Spigel, David R

Publication type:

Article

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.

Published in:

Oncologist, 2022, v. 27, n. 3, p. 175, doi. 10.1093/oncolo/oyab064

By:

Sturgill, Emma G;
Misch, Amanda;
Jones, Carissa C;
Luckett, Daniel;
Fu, Xiaotong;
Schlauch, Dan;
Jones, Suzanne F;
Burris, Howard A;
Spigel, David R;
McKenzie, Andrew J

Publication type:

Article

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors.

Published in:

Oncologist, 2021, v. 26, n. 11, p. 925, doi. 10.1002/onco.13911

By:

Do, Khanh T.;
Chow, Laura Quan Man;
Reckamp, Karen;
Sanborn, Rachel E.;
Burris, Howard;
Robert, Francisco;
Camidge, D. Ross;
Steuer, Conor E.;
Strickler, John H.;
Weise, Amy;
Specht, Jennifer M.;
Gutierrez, Martin;
Haughney, Peter;
Hengel, Shawna;
Derleth, Christina Louise;
Yap, Timothy A.

Publication type:

Article

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer.

Published in:

Oncologist, 2021, v. 26, n. 2, p. e261, doi. 10.1002/onco.13591

By:

Sobrero, Alberto;
Lenz, Heinz‐Josef;
Eng, Cathy;
Scheithauer, Werner;
Middleton, Gary;
Chen, Wenfeng;
Esser, Regina;
Nippgen, Johannes;
Burris, Howard

Publication type:

Article

A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC‐0994 in Patients with Advanced Solid Tumors.

Published in:

Oncologist, 2020, v. 25, n. 10, p. 833, doi. 10.1634/theoncologist.2020-0292

By:

Weekes, Colin;
Lockhart, Albert;
LoRusso, Patricia;
Murray, Elaine;
Park, Erica;
Tagen, Mike;
Singh, Jatinder;
Sarkar, Indrani;
Mueller, Lars;
Dokainish, Hatem;
Shapiro, Geoffrey;
Burris, Howard

Publication type:

Article

A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial.

Published in:

Oncologist, 2019, v. 24, n. 12, p. e1409, doi. 10.1634/theoncologist.2018-0518

By:

Spigel, David R.;
Shipley, Dianna L.;
Waterhouse, David M.;
Jones, Suzanne F.;
Ward, Patrick J.;
Shih, Kent C.;
Hemphill, Brian;
McCleod, Michael;
Whorf, Robert C.;
Page, Ray D.;
Stilwill, Joseph;
Mekhail, Tarek;
Jacobs, Cindy;
Burris, Howard A.;
Hainsworth, John D.

Publication type:

Article

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575

By:

Shapiro, Geoffrey I.;
Kristeleit, Rebecca S.;
Burris, Howard A.;
LoRusso, Patricia;
Patel, Manish R.;
Drew, Yvette;
Giordano, Heidi;
Maloney, Lara;
Watkins, Simon;
Goble, Sandra;
Jaw‐Tsai, Sarah;
Xiao, Jim J.

Publication type:

Article

Relative Bioavailability of Pediatric Oral Solution and Tablet Formulations of Trametinib in Adult Patients With Solid Tumors.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 287, doi. 10.1002/cpdd.152

By:

Cox, Donna S.;
Allred, Alicia;
Zhou, YanYan;
Infante, Jeffrey R.;
Gordon, Michael S.;
Bendell, Johanna;
Jones, Suzanne;
Burris, Howard;
Orford, Keith

Publication type:

Article

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Published in:

Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55316-5

By:

Gounder, Mrinal;
Johnson, Melissa;
Heist, Rebecca S.;
Shapiro, Geoffrey I.;
Postel-Vinay, Sophie;
Wilson, Frederick H.;
Garralda, Elena;
Wulf, Gerburg;
Almon, Caroline;
Nabhan, Salah;
Aguado-Fraile, Elia;
He, Peng;
Romagnoli, Mathilde;
Hossain, Mohammad;
Narayanaswamy, Rohini;
Sadou-Dubourgnoux, Amel;
Cooper, Michael;
Askoxylakis, Vasileios;
Burris, Howard A.;
Tabernero, Josep

Publication type:

Article

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

Published in:

Journal of Hematology & Oncology, 2009, v. 2, p. 1, doi. 10.1186/1756-8722-2-20

By:

Raza, Azra;
Galili, Naomi;
Callander, Natalie;
Ochoa, Leonel;
Piro, Lawrence;
Emanuel, Peter;
Williams, Stephanie;
Burris III, Howard;
Faderl, Stefan;
Estrov, Zeev;
Curtin, Peter;
Larson, Richard A.;
Keck, James G.;
Jones, Marsha;
Meng, Lisa;
Brown, Gail L.

Publication type:

Article

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.

Published in:

2021

By:

Burris, Howard A.;
Chan, Arlene;
Bardia, Aditya;
Thaddeus Beck, J.;
Sohn, Joohyuk;
Neven, Patrick;
Tripathy, Debu;
Im, Seock-Ah;
Chia, Stephen;
Esteva, Francisco J.;
Hart, Lowell;
Zarate, Juan Pablo;
Ridolfi, Antonia;
Lorenc, Karen Rodriguez;
Yardley, Denise A.

Publication type:

journal article

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

Published in:

2020

By:

Voss, Martin H.;
Gordon, Michael S.;
Mita, Monica;
Rini, Brian;
Makker, Vicky;
Macarulla, Teresa;
Smith, David C.;
Cervantes, Andrés;
Puzanov, Igor;
Pili, Roberto;
Wang, Ding;
Jalal, Shadia;
Pant, Shubham;
Patel, Manish R.;
Neuwirth, Rachel l.;
Enke, Aaron;
Shou, Yaping;
Sedarati, Farhad;
Faller, Douglas V.;
Burris III, Howard A.

Publication type:

journal article

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.

Published in:

2014

By:

Yardley, Denise;
Noguchi, Shinzaburo;
Pritchard, Kathleen;
Burris, Howard;
Baselga, José;
Gnant, Michael;
Hortobagyi, Gabriel;
Campone, Mario;
Pistilli, Barbara;
Piccart, Martine;
Melichar, Bohuslav;
Petrakova, Katarina;
Arena, Francis;
Erdkamp, Frans;
Harb, Wael;
Feng, Wentao;
Cahana, Ayelet;
Taran, Tetiana;
Lebwohl, David;
Rugo, Hope

Publication type:

Erratum

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Published in:

2013

By:

Yardley, Denise A;
Noguchi, Shinzaburo;
Pritchard, Kathleen I;
Burris 3rd, Howard A;
Baselga, José;
Gnant, Michael;
Hortobagyi, Gabriel N;
Campone, Mario;
Pistilli, Barbara;
Piccart, Martine;
Melichar, Bohuslav;
Petrakova, Katarina;
Arena, Francis P;
Erdkamp, Frans;
Harb, Wael A;
Feng, Wentao;
Cahana, Ayelet;
Taran, Tetiana;
Lebwohl, David;
Rugo, Hope S

Publication type:

journal article

Everolimus Plus Exemestane in Postmenopausal Patients with HR<sup>+</sup> Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.

Published in:

Advances in Therapy, 2013, v. 30, n. 10, p. 870, doi. 10.1007/s12325-013-0060-1

By:

Yardley, Denise A.;
Noguchi, Shinzaburo;
Pritchard, Kathleen I.;
Burris III, Howard A.;
Baselga, José;
Gnant, Michael;
Hortobagyi, Gabriel N.;
Campone, Mario;
Pistilli, Barbara;
Piccart, Martine;
Melichar, Bohuslav;
Petrakova, Katarina;
Arena, Francis P.;
Erdkamp, Frans;
Harb, Wael A.;
Feng, Wentao;
Cahana, Ayelet;
Taran, Tetiana;
Lebwohl, David;
Rugo, Hope S.

Publication type:

Article

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, n. 12, p. 2073, doi. 10.1007/s00228-013-1580-y

By:

Wu, Huali;
Infante, Jeffrey R.;
Keedy, Vicki L.;
Jones, Suzanne F.;
Chan, Emily;
Bendell, Johanna C.;
Lee, Wooin;
Zamboni, Beth A.;
Ikeda, Satoshi;
Kodaira, Hiroshi;
Rothenberg, Mace L.;
Burris III, Howard A.;
Zamboni, William C.

Publication type:

Article

Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in CombinationWith Erlotinib in Patients With Solid Tumors.

Published in:

Oncologist, 2015, v. 20, n. 3, p. 245, doi. 10.1634/theoncologist.2014-0449

By:

Soria, Jean‐Charles;
LoRusso, Patricia;
Bahleda, Ratislav;
Lager, Joanne;
Liu, Li;
Jiang, Jason;
Martini, Jean‐François;
Macé, Sandrine;
Burris, Howard

Publication type:

Article

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors.

Published in:

Oncologist, 2010, v. 15, n. 12, p. 1253, doi. 10.1634/theoncologist.2010-0095

By:

TAN, ANTOINETTE R.;
DOWLATI, AFSHIN;
JONES, SUZANNE F.;
INFANTE, JEFFREY R.;
NISHIOKA, JENNIFER;
FANG, LEI;
HODGE, JEFFREY P.;
GAINER, SHELBY D.;
ARUMUGHAM, THANGAM;
SUTTLE, A. BENJAMIN;
DAR, MOHAMMED M.;
LAGER, JOANNE J.;
BURRIS III, HOWARD A.

Publication type:

Article

Radiation Recall with Anticancer Agents.

Published in:

Oncologist, 2010, v. 15, n. 11, p. 1227, doi. 10.1634/theoncologist.2009-0090

By:

BURRIS III, HOWARD A.;
HURTIG, JANE

Publication type:

Article

A Phase I Study of Weekly Topotecan in Combination with Pemetrexed in Patients with Advanced Malignancies.

Published in:

Oncologist, 2010, v. 15, n. 9, p. 954, doi. 10.1634/theoncologist.2010-0006

By:

BURRIS III, HOWARD A.;
INFANTE, JEFFREY R.;
JEWELL, ROXANNE C.;
SPIGEL, DAVID R.;
GRECO, F. ANTHONY;
THOMPSON, DANA S.;
JONES, SUZANNE F.

Publication type:

Article

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways.

Published in:

Oncologist, 2008, v. 13, n. 3, p. 289, doi. 10.1634/theoncologist.2007-0134

By:

Burris III, Howard;
Rocha-Lima, Caio

Publication type:

Article

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.

Published in:

Cancer Medicine, 2015, v. 4, n. 8, p. 1178, doi. 10.1002/cam4.467

By:

Sager, Philip T.;
Balser, Barbara;
Wolfson, Julie;
Nichols, Jean;
Pilot, Richard;
Jones, Suzanne;
Burris, Howard A.

Publication type:

Article

The evolving landscape of tissue‐agnostic therapies in precision oncology.

Published in:

CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 433, doi. 10.3322/caac.21844

By:

Subbiah, Vivek;
Gouda, Mohamed A.;
Ryll, Bettina;
Burris, Howard A.;
Kurzrock, Razelle

Publication type:

Article

Should next-generation sequencing tests be performed on all cancer patients?

Published in:

Expert Review of Molecular Diagnostics, 2019, v. 19, n. 2, p. 89, doi. 10.1080/14737159.2019.1564043

By:

McKenzie, Andrew J.;
Dilks, Holli H.;
Jones, Suzanne F.;
Burris III, Howard

Publication type:

Article

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.

Published in:

2022

By:

Brown, Jacqueline;
Scardo, Savannah;
Method, Michael;
Schlauch, Dan;
Misch, Amanda;
Picard, Shaita;
Hamilton, Erika;
Jones, Suzanne;
Burris, Howard;
Spigel, David

Publication type:

journal article

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Published in:

2018

By:

Rodon, Jordi;
Pérez-Fidalgo, Alejandro;
Krop, Ian E.;
Burris, Howard;
Guerrero-Zotano, Angel;
Britten, Carolyn D.;
Becerra, Carlos;
Schellens, Jan;
Richards, Donald A.;
Schuler, Martin;
Abu-Khalaf, Maysa;
Johnson, Faye M.;
Ranson, Malcolm;
Edenfield, Jeff;
Silva, Antonio P.;
Hackl, Wolfgang;
Quadt, Cornelia;
Demanse, David;
Duval, Vincent;
Baselga, Jose

Publication type:

journal article

The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.

Published in:

2018

By:

Moore, Kathleen;
Zhang, Zhi-Yi;
Agarwal, Shefali;
Burris, Howard;
Patel, Manish R;
Kansra, Vikram

Publication type:

journal article

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Published in:

2017

By:

Infante, Jeffrey;
Patnaik, Amita;
Verschraegen, Claire;
Olszanski, Anthony;
Shaheen, Montaser;
Burris, Howard;
Tolcher, Anthony;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Hynes, Scott;
Leohr, Jennifer;
Lin, Aimee;
Li, Lily;
McGlothlin, Anna;
Farrington, Daphne;
Westin, Eric;
Cohen, Roger;
Infante, Jeffrey R;
Verschraegen, Claire F;
Olszanski, Anthony J

Publication type:

journal article

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 993, doi. 10.1007/s00280-015-2694-y

By:

Tebbutt, Niall;
Kotasek, Dusan;
Burris, Howard;
Schwartzberg, Lee;
Hurwitz, Herbert;
Stephenson, Joe;
Warner, Douglas;
Chen, Lisa;
Hsu, Cheng-Pang;
Goldstein, David

Publication type:

Article

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 1, p. 125, doi. 10.1007/s00280-014-2480-2

By:

Bendell, Johanna;
Hong, David;
Burris, Howard;
Naing, Aung;
Jones, Suzanne;
Falchook, Gerald;
Bricmont, Patricia;
Elekes, Agnes;
Rock, Edwin;
Kurzrock, Razelle

Publication type:

Article

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 4, p. 861, doi. 10.1007/s00280-013-2267-x

By:

Papadopoulos, Kyriakos;
Burris, Howard;
Gordon, Michael;
Lee, Peter;
Sausville, Edward;
Rosen, Peter;
Patnaik, Amita;
Cutler, Richard;
Wang, Zhengping;
Lee, Susan;
Jones, Suzanne;
Infante, Jeffery

Publication type:

Article

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 829, doi. 10.1007/s00280-012-2043-3

By:

Burris, Howard

Publication type:

Article

Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 5, p. 699, doi. 10.1007/s00280-012-1960-5

By:

Infante, Jeffrey;
Keedy, Vicki;
Jones, Suzanne;
Zamboni, William;
Chan, Emily;
Bendell, Johanna;
Lee, Wooin;
Wu, Huali;
Ikeda, Satoshi;
Kodaira, Hiroshi;
Rothenberg, Mace;
Burris III, Howard

Publication type:

Article

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.

Published in:

2012

By:

Jones, Suzanne;
Infante, Jeffrey;
Thompson, Dana;
Mohyuddin, Adil;
Bendell, Johanna;
Yardley, Denise;
Burris, Howard

Publication type:

Report

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 5, p. 1229, doi. 10.1007/s00280-011-1817-3

By:

Girish, Sandhya;
Gupta, Manish;
Wang, Bei;
Lu, Dan;
Krop, Ian;
Vogel, Charles;
Burris III, Howard;
LoRusso, Patricia;
Yi, Joo-Hee;
Saad, Ola;
Tong, Barbara;
Chu, Yu-Waye;
Holden, Scott;
Joshi, Amita

Publication type:

Article

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 137, doi. 10.1007/s00280-011-1674-0

By:

Infante, Jeffrey;
Jones, Suzanne;
Bendell, Johanna;
Greco, F.;
Yardley, Denise;
Lane, Cassie;
Spigel, David;
Hainsworth, John;
Burris III, Howard

Publication type:

Article

Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 6, p. 1507, doi. 10.1007/s00280-011-1635-7

By:

Tsimberidou, Apostolia-Maria;
Lewis, Nancy;
Reid, Tony;
Burris, Howard;
Urban, Patrick;
Tan, Eugene;
Anand, Suraj;
Uehara, Cynthia;
Kurzrock, Razelle

Publication type:

Article

Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 5, p. 1045, doi. 10.1007/s00280-010-1398-6

By:

Burris, Howard;
Berman, David;
Murthy, Bindu;
Jones, Suzanne

Publication type:

Article